On June 28, 2023, Roivant Sciences surprised investors with its impressive Q4 performance, leading to a surge in its stock prices. The company’s financial results for the fourth quarter and fiscal year ending March 31, 2022, revealed a net loss of $352.01 million, marking a 15.01% decline compared to the previous year. Despite this setback, Roivant Sciences managed to surpass analysts’ predictions, with earnings per share of -$1.78 over the past four quarters. The company’s Q4 loss was offset by a remarkable 44.56% increase in revenue, surpassing all expectations. Consequently, Roivant Sciences’ shares experienced a significant boost following the release of its earnings report.
Roivant Sciences Ltd.
ROIV
Neutral
Updated on: 28/09/2023
Financial Health
Weak
Debt to equity ratio: Buy
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Strong Sell
ROIV Stock Performance and Financial Analysis: June 28, 2023
ROIV stock had a mixed performance on June 28, 2023. The stock opened at $9.15, slightly lower than the previous day’s closing price of $9.18. Throughout the day, it traded in a range of $8.41 to $9.19. The trading volume was significantly higher than the average volume of the past three months, with 10,414,705 shares changing hands.
ROIV has a market capitalization of $7.4 billion. The company’s financial performance has shown significant fluctuations. In the last year, it experienced a remarkable earnings growth of +65.27%. However, this year’s earnings growth has declined by -35.60%. Looking ahead, the company is expected to rebound with a projected earnings growth of +47.23% over the next five years.
The revenue growth of ROIV has been impressive, with a growth rate of +132.34% in the previous year. However, the company’s financial ratios raise some concerns. The P/E ratio is not available (NM), indicating that the company may not have positive earnings or may be in a loss-making position. The price/sales ratio is relatively high at 59.84, suggesting that the stock may be overvalued based on its sales. The price/book ratio of 4.11 indicates that the stock is trading at a premium compared to its book value.
It is worth noting that there is no available data on ROIV’s competitors, which makes it difficult to assess its relative performance within the industry. The last reporting date for the company was on June 28, 2023, which aligns with the stock performance data.
Based on the EPS forecast for this quarter, ROIV is expected to report a loss of -$0.36 per share. The company’s annual revenue for the previous year was $55.3 million, while it incurred a net loss of -$845.3 million. The net profit margin is a concerning -1,528.89%, indicating that the company’s expenses exceed its revenue by a significant margin.
Overall, the stock performance of ROIV on June 28, 2023, was mixed, with the stock opening slightly lower than the previous close. The trading volume was significantly higher than the average volume, indicating increased market activity. The company’s financial performance has shown fluctuations, with impressive revenue growth but declining earnings growth this year. Investors should closely monitor the company’s financials and industry dynamics to make informed investment decisions.
ROIV Stock Shows Positive Performance with Analysts Predicting 60% Increase: Buy Roivant Sciences Ltd Shares
ROIV stock had a positive performance on June 28, 2023, based on the information provided by CNN Money. The 12-month price forecasts from 8 analysts for Roivant Sciences Ltd had a median target of 14.50, with a high estimate of 23.00 and a low estimate of 11.00. This median estimate represents a +60.04% increase from the last price of 9.06. Furthermore, the current consensus among 9 polled investment analysts is to buy stock in Roivant Sciences Ltd. This rating has remained steady since June, indicating a continued positive sentiment towards the company’s stock. Looking at the financials, Roivant Sciences Ltd reported a loss of $0.36 per share for the current quarter. However, the company generated $18.9 million in sales during the same period. These numbers provide insights into the company’s financial performance, indicating a potential for growth in the future.
Discussion about this post